Farmaceutica (Romania) Performance
| RMAH Stock | 0.62 0.01 1.59% |
The firm shows a Beta (market volatility) of 0.26, which means not very significant fluctuations relative to the market. As returns on the market increase, Farmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding Farmaceutica is expected to be smaller as well. At this point, Farmaceutica R has a negative expected return of -0.27%. Please make sure to confirm Farmaceutica's maximum drawdown, skewness, accumulation distribution, as well as the relationship between the potential upside and kurtosis , to decide if Farmaceutica R performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Farmaceutica R has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Farmaceutica |
Farmaceutica Relative Risk vs. Return Landscape
If you would invest 75.00 in Farmaceutica R on September 3, 2024 and sell it today you would lose (13.00) from holding Farmaceutica R or give up 17.33% of portfolio value over 90 days. Farmaceutica R is generating negative expected returns and assumes 1.9559% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Farmaceutica, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Farmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Farmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Farmaceutica R, and traders can use it to determine the average amount a Farmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1398
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RMAH |
Estimated Market Risk
| 1.96 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Farmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Farmaceutica by adding Farmaceutica to a well-diversified portfolio.
About Farmaceutica Performance
By examining Farmaceutica's fundamental ratios, stakeholders can obtain critical insights into Farmaceutica's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Farmaceutica is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Things to note about Farmaceutica R performance evaluation
Checking the ongoing alerts about Farmaceutica for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Farmaceutica R help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Farmaceutica R generated a negative expected return over the last 90 days | |
| Farmaceutica R has some characteristics of a very speculative penny stock |
- Analyzing Farmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Farmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Farmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Farmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Farmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Farmaceutica's stock. These opinions can provide insight into Farmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Farmaceutica Stock
Farmaceutica financial ratios help investors to determine whether Farmaceutica Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Farmaceutica with respect to the benefits of owning Farmaceutica security.